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Abstract:  
   Adherence to the treatment regimen is essential to the success of highly active antiretro-
viral therapy for patients who are infected with HIV. The evidence suggests that poor ad-
herence to antiretroviral drug therapy is a major problem that has the potential to diminish 
effective viral suppression, promote viral resistance, and place patients at risk for hospital-
ization, opportunistic infections, and an increased risk of HIV transmission. The primary 
aim of this study was review was to find and identify current barriers that prevent people 
from adherence to antiretroviral therapy.  The chosen research method was descriptive lit-
erature review. Three databases were used for the literature search: CINAHL full text (EB-
SCO), ProQuest Hospital Collection and Medline (Ovid). Search was limited to articles 
from years 2010-2015. Articles on children, pregnant women, intravenous drug users, psy-
chiatric patients, post and pre-exposure prophylaxis patients were excluded from the study. 
After exclusion process 46 articles were accepted for the final analysis. The data was cate-
gorized by topics trying to make interpretations from the literature reviewed. Scheduling 
issues, stigma, adverse side effects and cost were the most commonly found adherence 
barriers. Scheduling issues and the adverse side effects seem to be universal barriers for 
patients all over the world. Stigma was more prominent barrier in articles conducted in 
African countries and cost was found to be a barrier in studies conducted in resource poor 
settings.  High self-efficacy beliefs and social support were the most common positive in-
fluences to adherence to ART that rose from the review. The need for new solutions and 
innovations rose from the results of this review to support patients in scheduling issues nad 
remembering to take pills in correct time. Furthermore further interventions that effectively 
target stigma are warranted. Consideration of how healthcare systems and policy can 
promote and support self-efficacy is required.  
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FOREWORD 
 
This is the thesis conducted for the Master’s Degree Program in Global Health.  Antiretro-
viral therapy (ART) has made HIV a chronic manageable disease. Essential for the suc-
cess of ART is over 95% adherence rate. After 20 years of antiretroviral therapy several 
barriers remain to prevent patients to optimal adherence to ART. One afternoon in the 
Meilahti hospital A&E I had a patient who was dying of HIV related pneumonia, when 
asked why she had not taken her antiretroviral tablets she answered that the tablets were 
too big. Her answer got me thinking of the reasons why someone would not commit to a 
treatment that is lifesaving. Furthermore barriers to adherence still prevent people from 
reaching 95% adherence rate.
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1 INTRODUCTION 
In June 1981 the Centre for Disease Control and Prevention (CDC) in the US wrote in 
their weekly report about five previously healthy adult males who had gotten pneumo-
cystis pneumonia (Sutinen, 2012). This was the first indication of a pathogen, which later 
would be named human immunodeficiency virus (HIV), which would become the most 
destructive infectious agent in the 20th century (Mandell, 2005, p1655).  Due to increas-
ing information and tremendous strides in prevention and treatment in the last ten years, 
today the life expectancy of a person living with HIV is decades. It has changed from a 
lethal disease into a chronic condition, with life expectancy being the same of a person 
cured from cancer (Syrjänen, 2005). This is mostly due to the development of HAART 
(Highly active antiretroviral therapy), which is a combination drug therapy.  
 
According to the WHO there were 35 million people living with HIV worldwide in the 
end of 2013. In the year 2013 1.5 million people died of AIDS related illnesses, which is 
35% less than in 2005 (WHO, 2015). WHO (2015) estimates that ART (Antiretroviral 
therapy) programmes averted 7.6 million [6.9 – 8.4 million] deaths between 1995 and 
2013. Antiretroviral therapy has dramatic positive effects on the lifespan and quality of 
life of people living with HIV. Antiretroviral therapy reduces the load of human immu-
nodeficiency virus (HIV) and increases CD4 cell counts, delaying progression to acquired 
immune deficiency syndrome (AIDS) and reducing morbidity and mortality (Wasti, 
2012). 
 
Eradication of HIV infection cannot be achieved with the available antiretroviral (ART) 
therapy, even when new, potent drugs are added to a regimen that is already suppressing 
plasma viral load below the limits that can be detected with current lab tests (AIDSinfo, 
2015, p. D-1). The antiretroviral therapy is permanent once started (Sutinen, 2012). The 
patient’s adherence to the therapy is essential for its success (Syrjänen, 2005). High level 
of sustained adherence is necessary to (1) suppress viral replication and improve immu-
nological and clinical outcomes; (2) decrease the risk of developing ARV drug resistance; 
and (3) reduce the risk of transmitting HIV (WHO, 2013).  
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In year 2000 the rates of non-adherence to antiretroviral therapy among HIV-positive 
adults ranged from 37 to 70% (Murphy 2000). Substantial rates of non-adherence have 
been widely described in the literature despite a multitude of interventions that have been 
formulated to support and promote high levels of treatment adherence (Sherr, 2008). Ten 
years later and the adherence levels are not much better. Adherence, for example, in the 
USA to antiretroviral therapy remains relatively low, most researchers estimate median 
adherence to be 60-70% (Moitra, 2011). The adherence to the antiretroviral therapy is 
essential for it success. Understanding factors associated with adherence are critical in 
order to improve adherence interventions for people living with HIV. 
2 THEORETICAL FRAME 
2.1 Antiretroviral therapy 
The first medication against the human immunodeficiency virus (HIV) was taken into use 
in 1987, four years after HIV-1 was identified as the agent that causes AIDS (acquired 
immunodeficiency syndrome) (Mandell, 2005, p1655). Between the years 1995 and 2003 
fifteen new antiretroviral agents were approved for treatment of HIV. These included 
protease inhibitors, non-nucleoside transcriptase inhibitors (NNRTI’s) and a fusion in-
hibitor (Mandell, 2005, p1655). In mid-1990’s a better understanding of the dynamics, 
replication and drug resistance mechanisms of HIV cased a shift from single to combina-
tion drug therapy (Mandell, 2005, 1655). Currently there are over 30 different HIV med-
ications (AIDSinfo, 2015, p A-1). With the advent of highly active antiretroviral therapy 
(HAART), HIV-1 infection is now manageable as a chronic disease in patients who have 
access to medication and who achieve durable virologic suppression (Rathbun, 2015). 
2.2 Highly active antiretroviral therapy (HAART) 
The combination drug therapy against HIV is called highly active antiretroviral therapy 
(HAART). It is most commonly done with the combination of three different medications 
(Sutinen, 2012). There are currently six different classes of HIV drugs.  
 Nucleoside reverse transcriptase inhibitors (NRTIs)  
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)  
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 Protease inhibitors (PIs)  
 Integrase inhibitors (INSTIs)  
 Fusion inhibitors (FIs)  
 Chemokine receptor antagonists (CCR5 antagonists) (Rathbun, 2015) 
 
Each class of drug attacks the virus at different points in its life cycle as the virus infects 
a CD4+ T lymphocyte or other target cell (Rathbun, 2015).  The combination therapy 
generally includes at least two, and preferably three, different antiretroviral drugs from 
two or more different drug classes (AIDSinfo, 2015, pA-1). The selection of individual 
agents for an optimized background regimen should be based on the antiretroviral treat-
ment history, genotypic and/or phenotypic resistance results, drug-drug interaction po-
tential, and medication intolerance, with the goal of maximizing antiviral activity and 
adherence (Rathbun, 2015). The primary goals for antiretroviral therapy (ART) are to 
reduce HIV-associated morbidity and prolong the duration and quality of survival, restore 
and preserve immunologic function, maximally and durably suppress plasma HIV viral 
load and prevent HIV transmission (AIDSinfo, 2015, p. D-1). Excess mortality among 
patients with AIDS was nearly halved in the HAART era (see Figure 1.), but it remains 
approximately 5 times higher in patients with AIDS than in HIV-infected patients without 
AIDS.  
 
 
Figure 1. Changes in survival of people infected with HIV. As therapies have become 
more aggressive, they have been more effective, although survival with HIV infection is 
not yet equivalent to that in uninfected people. (Rathbun, 2015) 
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The CD4+ cell count thresholds for HAART initiation were recently raised from 350 to 
500 cells/mL in the United States and from 200 to 350 cells/mL in mid- and low-income 
countries (Rathbun, 2015). 
 
Drug resistance is one of the main issues related to HAART. Virus strains with reduced 
sensitivity to zidovudine, the first drug used to treat HIV infection, were first observed in 
1989, three years after it was introduced (Stevens, 2004). Resistance to every currently 
licensed antiretroviral drug has been observed (Stevens, 2004). Furthermore and they can 
have serious side effects, such as osteonecrosis and bone demineralization. Protease in-
hibitor therapy has been associated with hyperlipidemia, hyperglycemia, gastrointestinal 
symptoms, and body-fat distribution abnormalities (Lesho, 2003). Nonnucleoside reverse 
transcriptase inhibitors can cause rashes and hepatotoxicity, and nucleoside reverse tran-
scriptase inhibitors can cause lactic acidosis, hypersensitivity reactions, neuropathies, 
pancreatitis, anemia, and neutropenia. Malabsorption can occur if antiretroviral agents are 
taken improperly with regard to meals or if they are taken with certain other drugs or 
herbal remedies (Lesho, 2003). Some commonly prescribed drugs can cause dangerous 
drug toxicities if they are taken by patients who are also taking certain antiretroviral med-
ications (Lesho, 2003). 
2.3 Adherence to HAART 
According to several studies people do not like taking medications and have often skep-
tical attitude towards them (Enlund, 2013). It is known that negative or skeptical attitude 
towards medication is often related to poor adherence (Enlund, 2013). The word adher-
ence is preferred by healthcare providers, instead of words like compliance, as it indicates 
that the treatment plan is based on alliance or a contract between patient and physician, 
rather that patient passively following physicians orders (Enholm, 2013; Osterberg, 
2005). Medication adherence means taking your HIV medications when and how one is 
supposed to take them. Average rates for adherence in clinical trials have been found to 
be high, but rates of adherence for chronic conditions are only found to be 43 to 78% 
(Osterberg, 2005). 
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Strict adherence is the key to successful antiretroviral therapy (ART). Optimal adherence 
to HAART leads to HIV suppression, reduced risk of drug resistance, improved overall 
health, quality of life, and survival, as well as decreased risk of HIV transmission 
(AIDSinfo, 2015, p K-1). Patients must take 95 percent of their pills to achieve an 80 
percent likelihood of HIV suppression below 50 copies per mL. With less than 95 percent 
adherence, the probability of suppression to undetectable levels drops to less than 50 per-
cent (Lesho, 2003; Moitra, 2011; Syrjänen, 2005).  Failure to take medications regularly 
and reliably causes the virus to be exposed to suboptimal drug serum concentrations 
(Lesho, 2003). Non-adherence to ART, may lead to an increase viral load which may lead 
to drug resistance and loss of future treatment options (Syrjänen, 2005; AIDSinfo, 2015, 
p K-1).  Poor adherence is the major cause of therapeutic failure. Achieving adherence to 
ART is a critical determinant of long-term outcome in HIV infected patients (AIDSinfo, 
2015, pK-1). The adherence for ART is more challenging and more significant than in 
many other chronic diseases, such as diabetes or hypertension, their drug regimens remain 
effective even after treatment is resumed after a period of interruption (Syrjänen, 2005; 
AIDSinfo, 2015, p K-1). This is not the case with HIV. 
 
There is significant amount of research about the reasons behind poor adherence to an-
tiretroviral therapy. Antiretroviral therapies available in the 1990s involved a high pill 
burden and complex schedule combinations. The efficacy of the treatment was limited as 
frequent adverse events and the significant interference of treatment in patients’ lives 
made adherence difficult (Fumaz, 2008). In the early days of HAART in 1999 Proctor et 
al. found the top five barriers to HAART to be frequency and severity of side effects, 
conflicts with daily routine, dietary requirements, frequency of taking medication, num-
ber and dosage of medication. In the present decade advances have been made in HAART 
such as once-daily regimens have been developed to diminish the negative impact of 
treatment on quality of life and the appearance of less complex and toxic antiretroviral 
drugs has improved the management of HIV infection considerably (Fumaz, 2008), but 
even with the advances made adherence still remains an issue. Adherence is a multidi-
mensional concept that includes contextual, intrapersonal and behavioral factors (Fumaz, 
2008). Recent research has found several barriers affecting adherence to ART. These in-
clude structural barriers, such as food insecurity or geographic isolation and lack of re-
sources to pay for transportation to clinic (Ketz, 2013).  In study done in Botswana 
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(Weiser, 2003) found that overall economic situation was one of the main barriers, in 
addition to the cost of the ART, other economic constraints included additional medica-
tion expenses, lack of food, lack of money for food and lack of money for clothes for 
patients and for their children.  
 
As above studies of risk factors in resource-poor settings have focused on access to an-
tiretroviral and food and have shown these to be some of the main barrier for adherence 
to antiretroviral therapy. In contrast, risk factors for non-adherence in wealthier countries 
include depression, active drug and alcohol abuse, social instability, and low literacy 
(AIDSinfo, 2015, pK-1).  In a study by Harris et al (2011) it was found that no adherent 
participants felt less supported by family and perceived having less support for adherence 
itself.  Adherence has been found (Fumaz, 2008) to be related to beliefs about health and 
illness than to the characteristics of medication or level of knowledge about treatment. 
Fumaz (2008) found that adherent patients exhibited a higher perception of risk of devel-
oping the illness and of the benefits of therapy, higher self-efficacy and intention to ad-
here and were more influenced by the events that motivate medication intake. Further-
more incorrect beliefs about the medication and dosing, irregular daily schedule, stigma, 
lack of social support, poor provider-patient relationship, health-care system barriers 
(such as cost) and medication side effects (Murphy, 2000; Murphy, 2004; Sherr, 2008; 
Welsh, 2001).  
 
There are many adherence strategies that have been explored, direct observation of all or 
some doses of antiretroviral therapy is one of them.  In a study by Munoz (2011) imple-
mented community-based accompaniment with supervised antiretroviral therapy (CASA) 
in a resource poor setting and found that it had an impact not only on adherence but also 
on mortality within the ﬁrst 2 years, furthermore participants reported greater social sup-
port and reduced stigma compared with controls.  
2.4 Definition of terms 
Adherence: Someone behaving exactly according to rules, beliefs, etc.: (Cambridge dic-
tionary) 
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Adherence to medical regimen: Extent which patient take medication prescribed by their 
healthcare provider (Osterberg, 2005) 
 
Antiretroviral (ARV): acting, used, or effective against retroviruses (Merriam Webster 
Dictionary) 
 
Antiretroviral therapy/treatment (ART): treatment that suppresses or stops a retrovirus. 
One of the retrovirus is the human immunodeficiency virus (HIV) that causes AIDS 
(Medicine.net) 
 
Barrier:  a law, rule, problem, etc., that makes something difficult or impossible (Merriam 
Webster Dictionary) 
 
Highly active antiretroviral therapy HAART: combination of protease inhibitors taken 
with reverse transcriptase inhibitors; used in treating AIDS and HIV (Medicine.net)   
3 AIM OF THE RESEARCH 
The adherence to the antiretroviral therapy is essential for it success. Understanding fac-
tors associated with adherence are critical in order to improve adherence interventions for 
people living with HIV. The purpose of this literature review is to summarize the results 
of independent studies to determine current knowledge about the barriers to adherence to 
antiretroviral therapy and draw conclusions that might aid medical professional to support 
and encourage patients on antiretroviral therapy to adhere. The aim of the research is to 
find and identify current barriers that prevent people from adherence to antiretroviral ther-
apy. If there are for example cultural, geographical or demographic differences in the 
level of adherence and barriers to adherence. To answer the question: what are the current 
barriers that prevent people from adherence to antiretroviral therapy?  Having that 
knowledge will hopefully help the public health sector in developing new methods of 
concurring those barriers and to increase the level of adherence which has stayed on the 
same relatively low level since the ART started.  
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4 RESEARCH METHOD 
This research is done as a literature review. The purpose of a literature review is to ob-
jectively report the current knowledge on a topic and base this summary on previously 
published research (Green, 2006, p102). The chosen research method is descriptive liter-
ature review or also known as narrative literature review (Kangasniemi, 2013), which is 
a comprehensive narrative synthesis of previously published information (Green, 2006, p 
103). There are many good reasons to write a descriptive overview of literature: they pull 
many pieces of information together into a readable format, bring practitioners up to date 
with certain clinical protocols and are helpful in presenting a broad perspective on a topic 
and often describe development of a problem or its management (Green, 2006). 
 
Kangasniemi (2013) divide the descriptive literature method into four phases: formulation 
of the research question, selection of the material, synthesise and discussion. Green 
(2006) includes phase of limitations of the review. 
 
Setting the research question: The direction and focus of the descriptive review is defined 
by the research question (Kangasniemi, 2013). The research question should be explicit 
and focused so the phenomenon can be examined in debt (Kangasniemi, 2013).  
  
Sources of information, search terms & delimiting:  a detailed search of the literature is 
based upon a focused research question (Green, 2006). The most efficient way to begin a 
literature search is to use electronic databases (Green 2006, p108; Kangasniemi, 2013) 
The boundaries set in this step must be comprehensive enough to insure that the author 
may retrieve all relevant studies, but narrow enough to focus the effort on the relevant 
articles (Green, 2006, p.108). In this step it is important to briefly describe what selection 
criteria were used to include or exclude a study from the review (Green, 2006, p108; 
Kangasniemi, 2013) 
 
Synthesis: The information from the literature search is synthesized into evidence tables 
or comprehensive paragraphs, in order to tease out the differences in the results of differ-
ent studies (Green, 2006, p.110). Each piece of evidence should be extracted in the same 
fashion to help decrease the bias of the review (Green, 2006, p109). There is no single 
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way to write this section. Therefore it is essential to think clearly about what is being 
conveyed according to the objective of the overview (Green, 2006 , p 110) 
 
Discussion and limitations: In this phase the essential findings of the literature review are 
combined and summarised (Kangasniemi, 2013). Major areas of agreement and disagree-
ment in the literature should be discussed (Green, 2006, p 111). The discussion should tie 
the study into the current body of literature, provide its clinical significance, and make 
logical interpretations from the literature reviewed (Green, 2006, p.111). The weaknesses 
of the review should be addressed and mention areas for improvement (Green, 2006, p, 
111). 
4.1 Literature search 
Three databases were used for the literature search: CINAHL full text (EBSCO), 
ProQuest Hospital Collection and Medline (Ovid). A Boolean search was conducted 
across all the three databases. Search terms used were antiretroviral therapy and adher-
ence. When using the ProQuest used additionally word barriers. The search included ar-
ticles published between years 2010 to 2015. Search was limited to articles with full text 
available online, research done on adults and articles written in English language. Articles 
on specialized populations as children, pregnant women, intravenous drug users, psychi-
atric patients and post exposure prophylaxis patients were excluded from the review.  
 
The initial search of these three databases yielded 757 articles (see Figure 2.).  Of which 
640 were excluded after screening the titles and abstracts. Articles that were excluded 
were duplicates or did not appear to contain relevant data on adherence barriers or pro-
vided adherence data specific to a specialized population, which were excluded from the 
study. 117 journal articles were retrieved for full text review. Of these, 71 were excluded 
on the basis of the criteria for inclusion and exclusion or the full text was not to be found. 
The final sample included 46 articles (See appendix 1).  
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Figure 2.  757 articles were identified through electronic database search, after exclusion 
process 46 articles were accepted to the study. 
4.2 Analyses 
Out of the 757 articles found in the initial search, 46 of those were found relevant to 
review (see Appendix 1).  Those 46 articles were selected for the final analysis. The arti-
cles were read through individually and notes were taken in a form of a data analysis chart 
(see Appendix 2). Notes taken from each article included the reference, country were the 
study was conducted, sample, method used, ART adherence percentage, main findings 
on adherence barriers and comments (see Appendix 2). Comments included factors hav-
ing positive influence on ART adherence or other findings relevant to the barriers to ad-
herence. The data was categorized by topics trying to make logical interpretations from 
the literature reviewed. 
 
As each article was read and notes were taken of each article, information retrieved was 
formulated into paragraphs. The research results found about the barriers to antiretroviral 
therapy adherence was entered into the data analysis chart. Furthermore research result 
about positive influences on antiretroviral therapy adherence were entered into the data 
analysis chart. From the data analysis chart it could be seen that similar themes and bar-
riers were mentioned in several different articles. These barriers were gathered into a table 
Search done May 
2015: 757 articles 
identified through 
database search
757 articles 
screened by title 
and abstarct
• 640 articles 
excluded
117 full text 
articles were 
screened for 
eligibility
• 71 articles 
exluded
46 articles 
excepted into the 
review
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(see Table 2.) and the number of articles finding the same barriers were counted. As the 
data analysis chart was analyzed it was clear that several themes arose from the material. 
The results were divided into five categories: demographic barriers, psychological barri-
ers, regimen related barriers, patient belief related barriers and factors having a positive 
influence on ART adherence. 
4.3 Research ethics 
In a descriptive review, the findings of existing studies become raw data for analysis and 
interpretation (Boddy, 1999). One of the most important ethical considerations in a liter-
ature review is that it may not always be possible for the reviewer to identify the proce-
dures, for example around consent, that were used to ensure ethical practice in the study 
being reviewed (Boddy, 1999). I have selected studies that have been peer reviewed and 
trust that consent was followed in each of the reviewed studies. I assume that the subjects 
gave permission for activities that were similar in purpose as this review and even if they 
did not consent specifically to this review. I have done my best to ensure that I treat the 
work of existing researchers accurately and fairly. I have tried to avoid bias and be sys-
tematic in my analysis of the articles selected for the review.   
5 RESULTS 
The results were gathered from 46 articles (See Appendix 1) which were accepted to the 
final analysis. The articles were published between the years of 2011-2014. The studies 
varied vastly in method and sample size. Most of the studies were conducted by using a 
quantitative method, also qualitative and mixed methods were used and one literature 
reviews. The sample size varied from 27 (Elliot, 2011) to 7034 (Kong, 2012). The studies 
were conducted around the world. Eighteen of the studies were conducted in different 
African countries (see Table 1). Of these three studies were conducted in Nigeria 
(Afolabi, 2013; Okoror, 2013; Oku, 2013), three in South Africa (Magutu, 2011; Nel, 
2013; Peltzer, 2010),  two in Tanzania (Lyimo, 2014; Watt, 2010), two in Uganda (Sen-
komago, 2011; Tuller 2010), one in Egypt (Badahdah, 2011), one in Kenya (Kamau, 
2011), one in Democratic Republic of Congo (Musumari, 2013), one in Zambia (Nozaki, 
2011) and one in Togo (Potchoo, 2010). Three of the studies had subjects from more than 
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one country, one from Ethiopia and Uganda (Gustal, 2011), second from Uganda and 
Zimbabwe (Nyanzi-Wakholi, 2012) and the third was done by using the West Africa, In-
ternational epidemiological Database (Jaquet, 2010). 13 of the studies were done in the United 
States (Beer, 2014; Brown, 2013; Colbers, 2013; Kessler, 2011; Kong 2012; Kyser, 2011; 
Lucey, 2011; King, 2012; Okonsky, 2011; Saberi, 2011; Tyer-Viola, 2014; Vissman, 
2013; Wagner, 2012).  Six studies conducted in Asia, from which three in China (Fred-
riksen-Goldsen, 2011; Li, 2012; Li 2011), one in Vietnam (Van Tam, 2011), one is Cam-
bodia (Elliot, 2011) and one in Thailand (Li, 2010). Two the studies were conducted in 
South America, one in Peru (Curioso, 2010) and one in Brazil (Hanif, 2013), two in Eu-
rope,  one in Romania (Dima, 2013) and one in Estonia Uuskula, 2012) , and three in 
India (Saha, 2014; Vallabhaneni, 2012; Venkatesh, 2010) (See Chart 1.). One study was 
a Strategies for Management of Antiretroviral Therapy (SMART) study. Data from the 
SMART study were collected in 33 countries on 6 continents (O’Connor, 2013) and one 
literature review (Al-Dakkak, 2013).  
 
Africa 18 
US 13 
Asia 6 
India 3 
Europe 2 
South America 2 
Table 1. Countries where studies were conducted 
 
Adherence percentages was given in 28 out of the 46 articles. Most of the given adherence 
levels, not including three (Colbert, 2013; Maqutu, 2011; Wagner, 2012), were self-re-
ported percentages. Studies conducted in African countries had generally high adherence 
percentages, average of 84%. Lower percentages were reported in Nigeria (Oku, 2013), 
Togo (Potchoo, 2010) and South Africa (Maqutu, 2011). Studies done in East African 
countries of Tanzania (Lyimo, 2014; Watt, 2010) and Kenya (Kamau, 2011) adherence 
percentages were over 90%. There was eight articles done in the United States which gave 
the adherence percentage and it was an average of 64%.  
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5.1.1 Demographics 
Demographic barriers to adherence were found in twelve different articles. Most com-
monly found demographic characteristic for poor adherence was black race. It was found 
in six articles, which were all conducted in The United States (Brown, 2013; Colbert, 
2013; Kong, 2012; Kyser, 2011; Saberi, 2011; Wagner, 2013). In a study by Kyser (2011) 
they found that persons of black race/ethnicity were more than twice as likely to be non-
adherent to medications as white persons, which was not explained by employment or 
education. Kong (2012) found true racial disparity in antiretroviral medication adherence. 
Being female was found as a barrier in three articles (Hanif, 2013; Beer, 2014; Brown, 
2013).  Study done in Brazil (Hanif, 2013) found that women were found to have more 
severe side effects than men, leading to higher rates of ARV discontinuation among 
women, furthermore they found that  women experience challenges in accessing ARVs 
due to lack of knowledge, stigma and discrimination (Hanif, 2013).  Old age was found 
as a barrier in three articles (King, 2012; O’Connor 2013; Watt, 2010) and young age in 
four articles (Beer, 2014; Nozaki, 2011; Saha, 2014; Watt, 2010).  Saha (2014) found that 
patients aged < 30 years were more non-adherent to HAART than patients aged ≥ 30 
years.  Watt (2010) found that old age (over 50), to be a barrier, as well as young age 
(under 30).  
5.1.2 Regimen related barriers 
Most commonly found barriers to ART in the literature were related to the antiretroviral 
therapy regimen characteristics (See Table 2.). Scheduling, which was found as a barrier 
in 16 articles, was the commonly found barrier, it includes required time and effort to 
manage the medication schedule (Curioso, 2010; Dima, 2013; Kamau, 2011; O’Connor, 
2013; Oku, 2013), dosing frequency (Beer, 2014; Colbert, 2013; Finocchario-Kessler, 
2011; Okonsky, 2011; Vallabhaneni, 2012) or being too busy (Elliot, 2011; Kamau, 2011; 
Oku, 2013; Saha, 2014; Vallabhaneni, 2012).  Vallabhaneni (2012) found that lack of, or 
interruption of daily routine, have been cited commonly in studies both in resource-lim-
ited settings, and in the developed world as a barrier to adherence.  
 
Furthermore forgetfulness rose as one of the main barriers. It was found in 12 articles 
(Badahdah, 2011; Curioso, 2010; Elliot, 2011; Jaquet, 2010; Kamau, 2011; Li, 2010; 
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Lucey, 2011; Musumari, 2013; Oku, 2013; Potchoo, 2010; Saha, 2014; Senkomago, 
2011). One participant in a study by Curioso (2010) stated that ““I think that forgetting 
to take your medicines is that you simply miss the time, because you know that you have 
to follow a scheme, to follow a treatment”. Another statement:  “Sometimes, it happens 
that I forget that I have already taken my evening pills; in that case I will take another one 
just to be sure I don’t miss” (Musumari, 2013).  
 
Travel or being away from home was found in eight articles (Curioso, 2010; Elliot, 2011; 
Jaquet, 2010; Oku, 2013; Potchoo, 2010; Saha, 2014; Senkomago, 2011; Vallabhaneni, 
2012). Travel rose to be the second main factor of poor adherence. In a study conducted 
in India, majority of participants forgot to bring medicines when away from home, and 
changed daily routines when travelling (Saha, 2014). Pill burden was found in three arti-
cles (Nyanzi-Wakholi, 2012; O’Connor, 2013; Oku, 013) as a barrier. Studies were con-
ducted in Nigeria (Oku, 2013), in Uganda and Zimbabwe (Nyanzi-Wakholi, 2012) and 
O’Connor’s study which was conducted in 33 countries around the world.  Barriers re-
lated to regimen characteristics were mentioned in articles from all over the world.  
 
Treatment related adverse side-effects were found to be a barrier to adherence in 13 arti-
cles (Al-Dakkak, 2013; Badahdah, 2011; Beer, 2014; Curioso 2010; Dima,2013; Li, 
2010; Lucey, 2011; O’Connor, 2013; Okonsky, 2011; Potchoo, 2010; Saha, 2014; 
Uuskula, 2012; Vallabhaneni, 2012 ). It was the third most commonly found barrier that 
rose from the literature. Side effects included both negative symptoms that the participant 
attributed to the ART regimen and side effects that were anticipated to occur due to the 
ART regimen. As highlighted by one participant in a study by Curioso (2010) “When I 
started with the treatment I was nauseous all the time. I had headaches. I had a fever. I 
had cellulitis again. I experienced a lot of illnesses that I had never had before....I was 
very bad off”. Study by Vallabhaneni (2012) found that side effects of HAART, particu-
larly for those on Stavudine-containing regimens were the most common reason for non-
adherence. Side effects were found in studies conducted in several different countries on 
different continents.  
 
Cost of acquiring antiretroviral was the fourth most common barrier found from the arti-
cles (Badahdah, 2011; Curioso, 2010; Elliot, 2011; Hanif, 2010; Musumari, 2013; 
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Nozaki, 2011; Oku, 2013; Potchoo, 2010; Senkomago, 2011; Tuller, 2010; Vallabhaneni, 
2012 ). This includes travel cost to the facility providing the ARV and the cost of obtain-
ing them. In a study done in the Republic of Congo (Musumari, 2010) the participants 
expressed difficulty securing money for transportation to attend clinical visits or other 
medical-related expenses such as medical tests or clinical examination fees. This resulted 
in some of them missing their medication refill appointments or temporarily interrupting 
their medication. Articles finding cost as a barrier were done in mostly in resource poor 
settings or rural clinics. Like in Uganda (Tuller, 2010) where a participant stated “ You 
may fail to get the 10,000 [shillings] to bring you here, and you end up getting maybe 
1000, 2000, and when you get that little, you divert it to food and some medicine, and 
then wait until you get enough money to bring you to the clinic”.  It was found by Hanif 
(2010) that even within lower income population, respondents with higher levels of assets 
were significantly more likely to be adherent (Hanif, 2010). Vallabhaneni (2012) found, 
in a study conducted in India, that receiving care at a private clinic, where patients bear a 
greater burden of medical expenses, was associated with increased non-adherence. Lack 
of reminder device was found as a barrier in four articles (Elliot, 2011, Magutu, 2011; 
Nozaki, 2011; Van Tam, 2011), this included missing a cellphone or not owning a wrist 
watch. These studies were all conducted in a resource poor setting, in Cambodia (Elliot, 
2011), South-Africa, in rural area (Magutu, 2011), Zambia, also in rural area (Nozaki, 
2011) and Vietnam (Van Tam, 2011).  
5.1.3 Psychosocial barriers 
Stigma was the other most commonly found barrier that rose from the articles. It was 
mentioned in 16 (Afolabi, 2013; Badahdah, 2011; Curioso, 2010; Gustal, 2011; Kamau, 
2011;  Li, 2011;  Li, 2010; Lyimo, 2014; Musumari, 2013; Nozaki, 2011; Nyanzi-
Wakholi, 2012; Okoror, 2013; Peltzer, 2010; Van Tam, 2011; Wagner, 2012) out of the 
46 articles. Nine of the articles mentioning stigma as a barrier were done in Africa, one 
in South-America and rest in Asia.  None of the articles done in the US mentioned stigma 
as a barrier for adherence. In a study conducted by Masumari (2013), in Congo, a partic-
ipant states: “I went to live at my grandparents’ place; over there they were not aware of 
my disease, so I didn’t want them to know”. In a study conducted in Peru (Curioso, 2010) 
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a participant states: “I have to hide from my family so they do not know that I’m taking 
my ART medication. They do not know anything about my disease.” 
 
Depression was found as a barrier in nine articles (Beer, 2014; Bottonari, 2010; Finoc-
chario-Kessler, 2011; Jaquet, 2010; Kong, 2011; Nel, 2013; Saberi, 2011; Tyer-Viola, 
2014; Venkatesh 2010). Six of the nine articles finding depression as a barrier were con-
ducted in the US. Bottonaris’ (2010) results illustrated that, among clinically depressed 
individuals, higher levels of threat associated with acute life events prospectively pre-
dicted decreases in treatment adherence. Emotional distress was mentioned in three arti-
cles (Dima, 2013; Bottonari, 2010;  Finocchario-Kessler, 2011). As Bottonari (2010) 
found that results that suggest that many HIV-infected individuals experience substantial 
stress and chaos in their lives. . Drinking alcohol (five articles) and substance abuse were 
found as a barrier in seven articles (Beer, 2014; Jaquet, 2010; Kyser, 2011; Finocchario-
Kessler, 2011; Lyimo, 2014; King, 2012; Venkatesh, 2010). Kyser et al (2011) found that 
persons who drank three or more alcoholic beverages per day were 70% more likely to 
be non-adherent compared with those who drank less. 
 
 Seven studies (Badahdah, 2011; Dima, 2013;  Kamau, 2011; Okonsky, 2011; Uuskula, 
2012; Venkatesh, 2010; Wagner, 2012) listed feeling physically very good or bad to a 
barrier for adherence.  
 
Scheduling 16 
Stigma 16 
Adverse side effects 13 
Cost 12 
Forgetfulness 12 
Depression 9 
Travel 8 
Drinking of alcohol/substance abuse 7 
General health status 7 
Beliefs 7 
Black race  6 
Diagnosed long time  4 
Lack of reminder device 4 
Amount of pills 3 
22 
 
Availability of ARV 3 
Emotional distress 3 
Lack of knowledge 3 
Female 3 
Older age 3 
Rural  2 
Young age 3 
Detectable viral load 1 
Poor confidence 1 
Table 2. Number of times a barrier was found in studies 
5.1.4 Patient beliefs related barriers 
Belief related barriers were found in eleven, articles. These include beliefs about the 
antiretroviral therapy: that the medication would not help (Li, 2010; Nyanzi-Wakholi, 
2012; Uuskula, 2012 ), beliefs about the need not to adhere 100% (Beer, 2014, Brown, 
2013), perceiving adherence as difficult (Dima, 2013), lack of knowledge of the ART, 
religious beliefs (Badahdah, 2011; Jaquet, 2010), influenced by traditional healers and 
the use of herbal medication. The use of traditional herbal medication as a barrier was 
mentioned in three articles (Musumari, 2013; Oku, 2013; Peltzer, 2010) all done in 
African countries. Religious beliefs were both found to be a barrier and a facilitator of 
ART adherence. In study by Musumari  (2013) the participants belief that one’s disease 
was caused by witchcraft led a few participants to interrupt their medication and to use 
prayers and/or traditional medicines in search for potential cure. In a study by Badahdah 
(2011) Religious beliefs were found to be a facilitator to adherence to Antiretroviral 
therapy In contrast to a by Finocchario-Kessler (2011) where religious/spiritual beliefs 
predicted lower ART adherence. 
5.1.5 Factors having a positive influence on ART adherence 
Additionally to the barriers to antiretroviral therapy several factors which have a positive 
influence on adherence were mentioned in several articles (See Table 3.). In 12 out 
(Afolabi, 2013; Curioso, 2010;  Finocchario-Kessler, 2011; Fredriksen-Goldsen, 2011; 
Hanif, 2013; Li, 2012; Maquu, 2011; Nozaki, 2011; Peltzer, 2010; Vallabhaneni, 2012; 
Van Tam, 2011; Vissman, 2013)  of the 46 articles  good social support network was 
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mentioned as having a positive influence on antiretroviral therapy adherence. The benefits 
of a strong social support network was mentioned in articles from seven different coun-
tries from four different continents. Curioso, (2010) found that family and friends remind 
the participants to adhere to their ART. Participant stated: “My mom or my sister remind 
me to take my medicines” (Curioso, 2010). Self-efficacy was mentioned in seven differ-
ent articles (Beer, 2014; Brown, 2013; Colbert, 2013,; Finocchario-Kessler, 2011; 
Kamau, 2011; Li, 2011; Tyer-Viola, 2014) as having a positive influence on adherence to 
ART, four of the eight studies were conducted in the US.  
 
Social support net 12 
Self-efficacy 7 
Positive effects of ART 4 
Knowledge 4 
Fixed routine 1 
Reminder tool 1 
Religious beliefs 1 
Reduced pill load 1 
Table 3. Factors having a positive effect on ART adherence 
6 DISCUSSION 
A meta-analysis (Ortega, 2011) of patients in North America and Africa estimated that 
only 55% and 77% in these areas, respectively, achieved over 80% adherence. In this 
review African countries had generally high adherence percentages, average of 84%, 
lower percentages were reported in Nigeria, Togo and South Africa. 25 out of the 28 
adherence percentages were self-reported. Patient self-report data often overestimate ad-
herence due to recall bias, it is an easy method that has been shown to be valid using 
electronic drug monitors and virologic failure as reference measures (Holtzman et al, 
2015). The findings of this review are in accordance with previous studies where it has 
been found that majority of people participating in HIV programs in Africa are adherent 
(Kamau, 2011) and that levels of adherence are relatively high in HIV clinic studies in 
African countries (Halbrich, 1999). The low adherence percentage found in the US, av-
erage of 64%, is also in accordance with previous literature (Ortega, 2011). Previous re-
search has found that adherence is a concern in North America (Mills, 2006). 
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Black race as a demographic barrier to antiretroviral therapy came obvious in many of 
the studies done in the United States. Kong (2012) states that these racial disparities may 
be attributed to findings that show black patients are more likely to postpone medical 
care, have less access to care, and less trust in health care providers than white patients. 
This is in accordance with previous studies (Bogart, 2010; Mkanta, 2010; Simoni, 2012). 
This should be further studied and adherence strategies especially in the United States 
should pay attention to sensitivity to cultural and socioeconomic differences. Both young 
age and old age were found as a barrier to adherence. The articles that found age as a 
barrier to adherence were conducted in The US, in different African countries and India. 
There doesn’t seem to be a cultural aspect to age as a barrier.  
 
In accordance with earlier studies (Giffort, 2000; Nachega 2015; Martin 2013) regimen 
characteristics, such as being too busy, forgetfulness, traveling and scheduling, were 
found to be the main barrier for adherence. These seem to be a universal issue and rose 
as a barrier from studies conducted all over the world, similarly in studies conducted in 
resource poor setting and in the western world.  In a recent study conducted by Saberi et 
al (2015) common barriers were found to be: 'away from home' (21.9%), 'simply forgot' 
(19.6%), 'change in daily routine' (19.5%), and 'fell asleep/slept through dosing time' 
(18.9%). Forgetfulness has been identiﬁed as a major barrier to ART adherence (Wise, 
2008. To increase adherence to HAART, patients can be encouraged to use the alarm 
systems available on their cell phones, or any other device that would be carried with 
them during their working hours, to provide timely reminders on taking medication (Saha, 
2014). There are several studies testing reminder devices such as pagers, alarms and tel-
ephones (Hardy, 2011; Wise, 2008). This review found that not having a reminder tool 
was found to be a barrier in studies conducted in a resource poor setting.  According to 
Potchoo (2011), travel as a factor of non-adherence reveals the problem of the lack of a 
pill container containing at least all daily doses.  This review also confirms forgetfulness 
and scheduling issues continues to be common barriers despite the research and innova-
tions done to eliminate these barriers. New solutions are needed to aid the patients in 
reaching optimal adherence. More research would be suggested in finding ways to sup-
port the patients of reminding them to take their tablets in time and support the difficulties 
in scheduling.  
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This review found that adverse side effects was the most commonly arising single barrier 
to adherence. Patients who had side-effects were more likely to be non-adherent, and this 
has also been reported in several other studies conducted in both developed and develop-
ing countries (Blake, 2000; Wasti, 2012; Weiser, 2003). It is crucial to select ART regi-
mens that are tolerable and acceptable to patients. Drug-drug and drug-disease interac-
tions should also be minimized as these have the potential to create additional adverse 
effects (Holzman, 2015). Adherence interventions need to take into account side effects, 
and encourage patients to talk with their care providers about side effects they may be 
experiencing so that treatment substitutions if available can be made.  
 
HIV related stigma was found to be the most common barrier to ART. Internalized 
stigma, which is widespread among people living with HIV in sub-Saharan Africa, is also 
an important public health issue because it compromises ART adherence (Chen, 2015). 
Individuals living with HIV continue to report experiences of social isolation and dis-
crimination resulting from being HIV positive (Kamau, 2011).Stigma has been mentioned 
as a barrier for adherence in several previous studies done in African countries (Weiser, 
2003; Sekoni, 2012; Murrey, 2009). In accordance with these previous studies, this re-
view found that especially studies done in the African countries found stigma to be one 
of the profound barriers to adherence. Efforts to counter stigma have been recognized as 
essential to HIV prevention and treatment (Chan, 2015). Chen (2015) found that an in-
creases in ART coverage has led to decreases in HIV-related stigma in the general popu-
lation in sub-Saharan Africa, which may, in turn, have important downstream beneﬁts for 
HIV prevention and treatment. 
 
In accordance with previous studies this review found that depression is a risk factor for 
nonadherence to antiretroviral therapy (Yun, 2005; Sin, 2014). Depression was found as 
a barrier for adherence to antiretroviral therapy in nine articles. Depression has been iden-
tified as one of the most important mental health-related barriers to ART adherence (Nel, 
2011). Depression inhibits adherence due to low motivation to seek care; poor concentra-
tion resulting in forgetting to take pills on time; fatigue and loss of energy to attend clinic 
appointments; feelings of hopelessness about the future (Nel, 2011). Untreated depression 
is connected to poor adherence to antiretroviral therapy (Yun, 2005; Sin, 2014.). 
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This review found the cost to be a major barrier especially in resource poor countries. The 
cost of medical care and medications can be major barriers for patients, compromising 
clinic attendance and prescription ﬁlls (Holtzman, 2015). Weiser (2003) found that over-
all economic situation was one of the main barriers in Botswana, most patients in Africa 
do not have access to subsidized or affordable ARVs. Households have been facing large 
financial burdens due to loss of income support from family members who die of the 
disease as well as increasing costs of treatment of HIV infection/AIDS and associated 
opportunistic infections (Weiser, 2003). In a study by Wasti (2012) money emerged as 
the greatest barrier, even if free-of charge ART was provided. The cost of diagnostic tests 
and travel costs must be paid for by patients as most respondents reported economic wor-
ries relating to the costs of transport, prescription, and charges for diagnosis.  
 
A study by Atkinson (2009) found that with poor medication self-efﬁcacy, incorrect be-
liefs about the treatment and the disease, lower optimism, and poorer understanding of 
treatment were associated with worse medication adherence. Wasti (2012) found that pa-
tient’s beliefs regarding treatment strongly influence their medical decision-making. They 
found that patients who believed in the efficacy of ART are more likely to adhere. These 
studies support the findings of this review which found that beliefs that the medication 
would not help (Li, 2010; Nyanzi-Wakholi, 2012; Uuskula, 2012 ), beliefs about the need 
not to adhere 100% (Beer, 2014; Brown, 2013), perceiving adherence as difficult (Dima, 
2013), lack of knowledge of the ART were barriers to adherence.  High self-efficacy be-
liefs were found in eight articles as having a positive influence on adherence to antiretro-
viral therapy. Fear of doing worse without adhering to ART was a prime motivator for 
adherence. This review found that religious beliefs were both a barrier and facilitator of 
ART adherence.  Previous studies have identified beliefs in spiritual healing and/or be-
liefs around the causes of HIV to impact negatively on ART adherence (Musumari, 2013). 
Wasti (2012) found religious beliefs being a barrier, for example during Ramadan people 
would not take their medication.  
 
Despite many barriers, two major factors: self-efficacy and social support, were identified 
as facilitators of adherence to ART. It has been found in previous studies that and self-
efficacy is directly related to increased adherence (Adefolalu, 2014; Johnsson 2006; 
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Luszczynska, 2007; Martin, 2013). Self-efficacy can be defined as “people’s self-efficacy 
beliefs determine their level of motivation, as reflected in how much effort they will exert 
in an endeavour and how long they will persevere in the face of obstacles” (Zulkosky, 
2009, p101). These results highlight the importance of patients being informed, actively 
involved in the treatment process, and competent to manage their own treatment. In this 
review the most commonly found factor for supporting adherence to ART was social 
support. Social support from family, friends, and neighbours can help patients maintain 
clinic visits and medication adherence, as these supports often provide moral encourage-
ment and healthcare assistance through transportation and reminders (Holtzman, 2015). 
Social support is associated with improved adherence to ART among those who disclosed 
their HIV status to household members or friends and acquaintance networks (Waddell, 
2006). 
7 CONCLUSION  
This review found that the most common barriers to adherence to antiretroviral therapy 
that rose from the reviewed literature were scheduling, stigma, adverse side effects, cost 
and forgetfulness. The barriers have stayed much the same since antiretroviral therapy 
started.  The most common barriers listed by Proctor et al in 1999, were side effects and 
conflicts with daily routine are still the barriers which cause patients not to be able to 
adhere completely to antiretroviral therapy. Factors having a positive influence on adher-
ence to antiretroviral therapy that rose from the articles review were having a good social 
support network and self-efficacy. It is necessary to recognize and overcome the key bar-
riers and promote measures to facilitate adherence. 
 
Scheduling issues, forgetfulness and adverse side effects seem to be universal barriers 
which rose from studies conducted all over the world.  Stigma was more prominent barrier 
in articles conducted in African countries and cost was found to be a barrier in studies 
conducted in resource poor settings.  
 
The review found scheduling and forgetfulness being some of most common barriers in 
adherence to antiretroviral therapy. Solutions and innovations have been done to eradicate 
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these barriers. Electronic reminder devices, including cellular phones, are growing in pop-
ularity as aides for patients who take frequent medications, but there is no profound evi-
dence found that would support their efficiency (Hardy, 2011; Wise, 2008) as these bar-
riers still are common. The need for new solutions and innovations rose from the results 
of this review to support patients in scheduling issues and remembering to take pills in 
correct time. 
 
In this review stigma was found to be the main barrier in adherence to antiretroviral ther-
apy, especially in studies conducted in Africa. Efforts to counter stigma have been recog-
nized as essential to HIV prevention and treatment (Chen, 2015). Reductions in HIV-
related stigma has been successful but still people continue to present for treatment at late 
stages of disease, and the stigma of HIV remains a major challenge. Interventions that 
effectively target stigma are warranted.  
 
Self-efficacy was found to be one of the most common positive influence on antiretroviral 
therapy adherence. One strategy in supporting adherence, therefore, can be to support 
taking antiretroviral therapy and support the belief in one’s ability to cope (Martin, 2013). 
Consideration of how healthcare systems and policy can promote and support self-effi-
cacy is required.  
 
As found is this review research is usually been carried out in already adherent patients 
with chronically suppressed viral loads. A subject for future research would be to find 
those who are non-adherent and find out the reasons behind the non-adherence.  
8 LIMITATION 
It is not easy to recognize the reviews limitations as the writer of the review have been so 
deeply involved with the material. I have tried to retrieve the data from the articles in a 
consistent and systematic fashion. I have done the synthesis of the information retrieved 
from the articles as objectively and clearly as possible, using the data analysis chart and 
tables as a tool to help with the synthesis process. I have tried to present the process used 
as clearly as possible so that it would be easy for the reader to follow the process used.  
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Since the descriptive overview already includes the biases of the authors of the articles 
included I have tried to be unbiased in my approach to the review.   
 
One of the strengths of the review is the large number of studies it involved and the vast 
material supporting the review findings.  I chose to use only articles that are available 
online. It is difficult to know if my results would have been the same if I had chosen also 
articles from other sources. I chose three databases to conduct my literature search. These 
databases were offered free of charge by the Diaconia University of Applied Sciences 
library services. These databases were chosen on the basis that they offer a vast collection 
of full text articles.  
 
The chosen method was descriptive literature review. There is no defined structure of 
writing a descriptive review. It is suggested that proper descriptive overview should cri-
tique each article included but others authors say that this is not necessary (Green, 2006). 
I have chosen not to do an individual critique of the articles. I chose to use data analysis 
chart and tables to assist in writing the results.  
 
Weaknesses of the review are the vast differences in the studies included. The articles 
included studies conducted with different methods to very different sample sizes. This 
makes the assessment of the fact that are the findings of the individual studies comparable 
with each other difficult. I tried to consider this as I chose not to make a difference in the 
emphasis or how common each barrier was within the participants in the reviewed arti-
cles. For example forgetfulness might have been a barrier in a single study for 21.9% of 
the participants and another study to 12% of the participants. In the synthesis of the results 
I have chosen to only list the barriers mentioned in each article and not how common they 
were in one individual article. By reviewing the articles chosen for this literature review 
I have been able to find answers to my research question of currents barriers to antiretro-
viral therapy adherence.  
 
All of the studies in this review were conducted, exception of one study (Masumari, 
2012), to patients who were already adherent, patients attending clinics with chronically 
suppressed viral loads. This gives a different picture of the barriers to adherence than if 
the studies would have been conducted with non-adherent patients. 
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9 CRITICAL REVIEW 
This thesis was done as a descriptive literature review to find out the current barriers 
preventing patients on antiretroviral therapy to adhere to their regimen.  It is taking re-
search articles and forming answers to the research question by conducting a narrative 
overview of the reviewed articles. The thesis consists of nine parts: introduction, theoret-
ical framework, aim of the research, research method, results, discussion, conclusion lim-
itations and critical review.  
 
Methodology chosen is descriptive literature review. Literature review is beneficial in 
providing insight into findings of other studies and forming a narrative synthesis of pre-
viously published information (Green, 2006). It is helpful in presenting a broad perspec-
tive on a topic like antiretroviral adherence. Descriptive literature reviews are great papers 
to read to keep up to date with currents knowledge on a subject but descriptive literature 
reviews are often the weakest forms of evidence for making clinical decisions in regard-
ing patient care (Green, 2006). For this research question the method was sound as this 
review tries to find out the current barriers to ART adherence.  
 
Authors of descriptive reviews are often experts of the field studied (Green, 2006), I did 
not have vast knowledge or experience of antiretroviral therapy before writing this re-
view. But it is also suggested that some experts are less likely to adhere to methodological 
rigor when writing a descriptive literature review that non-experts (Green, 2006). I have 
tried my best to be objective and methodological while conducting this review.   The 
weakness of this methodology is that it is easy to present opinions oriented arguments 
rather than objective conclusions based on the arguments. The critical factor of writing a 
descriptive literature review is to use good methods. I found this difficult, especially in 
the synthesis phase where there is no systematic method to follow and provide structure.  
I have included a vast number of articles in the review in hopes of creating a significant 
knowledge base from which draw a conclusion. 
  
Selecting the information from the primary articles is subjective, and lacks explicit crite-
ria (Green, 2006). I chose to gather the following information from each article: the ref-
erence, country were the study was conducted, sample, method used, ART adherence 
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percentage, main findings on adherence barriers and comments. This information was 
gathered into a data analysis chart. Studies were very different in sample size and method. 
I was aware of this and tried to take it into consideration when choosing how to combine 
the information arising from different articles and synthesizing it. All of the articles in-
cluded in the review and the articles supporting the findings are peer-reviewed research 
articles. Furthermore government agency reports and online pages are used to provide 
background information.  
 
The conclusion arising from the review is supported by previous research. As stated ear-
lier the selecting of the information from the primary articles is subjective so it is not 
guaranteed that another interpretation could not be plausible. But as the previous research 
strongly supports the review findings I am convinced I have been able to draw the correct 
conclusions from the data reviewed.  
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APPENDIX 2 
Appendix 2. Data analysis chart 
Country Reference Sample Method ART adherence 
≥95%, self-re-
ported 
Findings Comments 
Nigeria, Osogbo 1.Afolabi et l. 2013 379 adults-230 
women, 149 men 
Mix method, Descriptive 
cross sectional study 
87,9% Individuals with good so-
cial support were adherent 
to ART.  
 
There is need to edu-
cate and train family 
caregivers on stigma 
reduction and how to 
care and support their 
HIV positive rela-
tives. 
 2. Al-Dakkak et al 
2013 
 Literature review-meta 
analyses 
 Adherence to ART was 
significantly lower in pa-
tients with non-specific 
AEs (treatment related ad-
verse events) than in pa-
tients who did not experi-
ence AEs 
Patients with specific 
AEs such as fatigue, 
taste disturbances  
and nausea less likely 
to adhere  
Egypt 3.Badahdah et al. 
2011 
27 women Qualitative study, inter-
view 
 fear of stigma, costs asso-
ciated with obtaining and 
taking ART, forgetfulness, 
physical discomfort from 
side effectshad a negative 
impact on their adherence.  
Tremendous benefits 
they gained. In this 
study, religious be-
liefs acted as facilita-
tors 
  
United States 4.Beer et all 2014 3606 aduts-2636 
men, 914 women, 
56 transgender 
Mixed method, face-to-
face interviews and med-
ical record abstractions, 
The Medical Monitoring 
Project (MMP) 
86% Barriers for poor adher-
ence: younger age, female 
gender, depression, stimu-
lant use, binge drinking), 
dosing frequency, side ef-
fects. self-efficacy, beliefs 
about the need for adher-
ence to prevent resistance 
Poorer adherence to 
ART with patients di-
agnosed for more than 
10years ago. 
 
United States 5. Brown et al 2013 116 adults-49 
women, 67 men 
Quantitative study, sur-
vey 
61% Positive effects: adherence 
self-efficacy. 
Non adherence: women , 
racial minorities, beliefs 
that do not support a goal 
of 100% adherence 
. 
United States 
Pennsylvania, Ohio 
6. Colbert et al. 
2013 
302 adults-89 
women, 213 men 
Quantitative. Random-
ized control trial 
67,71% Elec-
tronically meas-
ure 
Poor adherence to be sig-
nificantly related to black 
race, detectable viral load 
and  Greater medication 
adherence was 2-3 number 
of medications, higher 
self-efficacy beliefs, 
there is no statisti-
cally significant asso-
ciation between HIV 
medication adherence 
and functional health 
literacy 
Peru, Lima 7. Curioso et al 
2010 
31 adults-28 men, 3 
women. Recourse 
poor setting 
Qualitative study, In 
depth interview 
- Most common barriers for 
ART adherence: side ef-
fects, forgetting, inconven-
ient schedule, financial 
burden, travel, stigma 
Facilitators for adher-
ence: fixed routine, 
understanding the 
need for adherence, 
knowledge, seeing 
positive results, use of 
a reminder tool 
Romania 8. Dima et al 2013 312 young adults 
(18-25 years)-164 
women, 148 men. 
Quantitative study, 
Questionnaire, CEAT-
VIH 
84% Low ART adherence more 
likely: patients feel physi-
cally better or worse, emo-
tionally distressed, if they 
perceive adherence diffi-
cult: requiring time and ef-
fort to the medication 
schedule, feel less satisfied 
Poor adherence if 
have less confidence 
in their ability to ad-
here 
  
with their treatment, expe-
rience more side effects 
and have lower outcome 
expectations. 
Cambodia 9. Elliot et al 2011 27 adults Qualitative study, in 
depth interview 
 attributed to forgetting, be-
ing busy, travelling or be-
cause of lack of a reminder 
device. 
Availability of ART poor.  
ART considered a 
gift, privilege. high 
prices in the private 
sector, patients shar-
ing ART with people 
who had not been 
able to access ART or 
selling antiretroviral 
drugs in order to buy 
food 
United States, Mid-
west 
10. Finocchario-
Kessler et al. 2011 
204 adults-51 
women, 153 men 
Quantitative study, Ran-
domised controlled trial 
59% Barriers: depression, per-
ceived stress, alcohol use, 
CD4 and viral load counts, 
frequency of dosing, social 
support, self-efficacy, ex-
perience with ART. 
Facilitators for adherence: 
autonomous support from 
friends, family to make de-
cisions regarding treat-
ment, autonomous regula-
tion, positive coping styles 
religious/spiritual be-
liefs predicted lower 
ART adherence 
China 11. Fredriksen-
Goldsen et al 2011 
113 adults survey 
20 adults  interview 
Mix –method study  Patients with family sup-
port report superior ART 
adherence. Also, gender 
(being female) and less 
time since ART initiation 
are significantly related to 
superior adherence. 
 
Ethiopia, Uganda 12. Gustal et al 
2011 
118 adults Qualitative semi-struc-
tured interview 
 peer counsellors as facili-
tators of adherence, 
avoiding or reducing 
stigma, also requires 
specific attention 
  
Brazil, Rio de Janeiro 13. Hanif et al. 2013 632 adults- 196 
women, 429 men, 7 
transgender, health 
clinics 
Quantitative, Cross sec-
tional survey 
84% Having one child, high so-
cial support and high asset 
index has positive associa-
tion with ART adherence, 
being a women a negative 
association 
wealth plays 
a role in adherence 
even in the context of 
free health 
services and medica-
tion, and gender 
West Africa, Interna-
tional epidemiologi-
cal Database to Eval-
uate AIDS (IeDEA) 
initiative 
14.Jaquet et al. 2010 2920 Adults-1838 
Côte D’Ivoire, 486 
Benin, 596 Mali 
Quantitative study, Cross 
–sectional study 
91,8% Poor adherence to ART: 
being busy or simply for-
got, being away from 
home, being out of stock 
for HAART because of the 
pharmacy, being out of 
stock of HAART at home, 
being depressed  and being 
influenced by traditional 
healers or religious leaders 
Alcohol consumption 
and hazardous drink-
ing is associated with 
non-adherence to 
HAART 
Kenya 15. Kamau et al. 
2011 
354 adults-253 
women, 101 men 
Quantitative research-
questionnaire 
94,5% Reasons for lack of adher-
ence: busy with other 
things, simply forgot, did 
not want others to notice 
you taking medications, 
felt sick, felt good, had 
problem taking medication 
at specific times ,slept 
through the dose. Only 1% 
indicated missing the dose 
because they ran out of 
pills 
found a significant re-
lationship between 
coping self-efficasy 
and adherence to 
ART. 
United States 16. Kong et al 2012 7034 adults- 66% 
black Americans, 
multi-state medical 
database 
Quantitative study Ret-
rospective cohort study 
- black race was signifi-
cantly 
associated with decreased 
odds of ART adherence. 
presence of depres-
sion did not 
further enhance the 
already existing racial 
disparity. 
depressed patients not 
on 
  
antidepressant had 
worse adherence than 
once one medication, 
also had lower adher-
ence 
compared to the non-
depressed patients 
United States 
SUN study (n Den-
ver, Colorado; Min-
neapolis, Minnesota; 
Providence, Rhode 
Island; and St. Louis, 
Missouri.) 
17. Kyser et al. 
2011 
528 adults-118 
women, 410 men 
Quantitative study,Lon-
gitudinal prospective co-
hort study 
84% associated with non-adher-
ence: black race, being un-
employed and looking for 
work, having been diag-
nosed with HIV ]5 years 
ago, drinking three or 
more drinks per day,  hav-
ing not engaged in any 
aerobic exercise in the last 
30 days 
 
China, Anhui pro-
vence 
18. Li et al 2012 66 adults-16 
women, 40 men 
Mixed method, interview 81,8% family members and 
friends sometimes or fre-
quently reminded them to 
take medicine 
not find a significant 
association between 
adherence to ART 
and demographic 
characteristics,  
China 19. Li et al 2011 202 adults-8 
women. 144 male 
Quantitative study 87%  high self-efficacy for dis-
ease management was a 
predictor for good medica-
tion adherence, which was 
effected by hiv stigma 
 
Thailand 20.Li et al. 2010 386 Adults- 259 
women, 126 male 
Quantitative study, Cross 
sectional survey 
69% Poor adherence due to: 
forgetting, afraid of stigma 
if their HIV status was dis-
closed, : trouble visiting 
the doctor, running out of 
medication, not under-
standing the medication or 
believing that the medica-
tion would not help,  being 
the presence of de-
pressive symptoms 
proved to be a barrier 
to ART adherence. 
Better access to care, 
positive family com-
munication and HIV 
disclosure were sig-
nificantly associated 
  
too sick to retrieve the 
medication from the hospi-
tal, wanting to avoid side-
effects. 
with better ART ad-
herence 
United States 21. Lucey et al 2011 46 adults-7women, 
39 men, with sen-
sory neuropathy and 
HIV 
Quantitative study, ques-
tionnaire 
 Fear f side effects and for-
getfulness, which was re-
lated to pain poor adher-
ence 
 
Tanzania 22. Lyimo et al 
2014 
158 adults Quantitative study, inter-
view, structured ques-
tionnaire 
100% adherence was negatively 
affected by alcohol use, 
self-stigma, and denial 
 
South Africa 23. Maqutu et al 
2011 
688 adults-  Quantitative study, data 
analysis 
79% pill counts 
data 
negative association 
HAART adherence time 
interval between succes-
sive clinic visits. 
cell phone ownership, liv-
ing with a partner, two-
way interaction terms, rea-
son for taking an HIV test, 
age with gender and edu-
cational level were still as-
sociated with optimal ad-
herence 
rural site, patients 
able to maintain high 
levels of adherence 
with longer intervals 
between successive 
visits 
United States, Hou-
ston 
24. Marks King et al 
2012 
326 adults-91 
women, 235 men 
Low-income 
Quantitative study, Ran-
domised controlled trail 
60,4% the level of nicotine de-
pendence, illicit drug use, 
alcohol use, and older age 
were each significantly as-
sociated with nonadher-
ence to ART. 
 
Democratic Republic 
of Congo 
25. Musumari et al 
2013 
38 adults-24 
women, 14 men 
Qualitative study-semi-
structured interview 
 Food insecurity, financial 
constraints, forgetfulness, 
fear of disclosure main 
reasons for poor ART ad-
herence 
Patients with re-treat-
ment and lost –to fol-
low up were also in-
terviewed 
South Africa 26. Nel et al 2013 101 adults-83 
women, 18 men 
Quantitative study  non-perfect adherence 
were approximately three 
 
  
times more likely symp-
toms of depression  
Zambia-rural area 27. Nozaki t al 2011 518 adults-297 
women, 206 men 
Quantitative study- semi 
structured interview 
88% Non adherence: younger 
age, higher travel ex-
penses, stigma, time of 
dose from the position of 
the sun, pressure to share 
ARV.  
Positive to adherence: 
family support 
Uganda & Zimbabwe  28. Nyanzi-Wakholi 
et al 2012 
82 Adults- 42 
women, 40 men 
Qualitative study, focus 
group discussion 
 fear of deteriorating. 
Stigma, amount of pills 
 
Strategies for Man-
agement of Antiretro-
viral Therapy 
(SMART) study. 
Data from the 
SMART study were 
collected in 33 coun-
tries on 6 continents 
29. O’Connor et al. 
2013 
5472 Randomized trial, quan-
titative  
Over 80% suboptimal adherence 
were black race, protease 
inhibitor–containing regi-
mens, greater pill burden, 
higher maximum number 
of doses per day, and 
smoking. associated with 
higher adherence: older 
age, higher education, re-
gion of residence, episodic 
treatment, higher latest (at 
the time of adherence) 
CD4+ T-cell count, and 
being prescribed concomi-
tant drugs  
found that among 
PI/NNRTI drugs, 
ATV, ATV/r, FPV, 
IDV, IDV/r, and 
LPV/r were associ-
ated with suboptimal 
adherence, compared 
with EFV. LPV/r and 
IDV are typically be-
lieved to be associ-
ated with higher rates 
of side effects and 
were prescribed with 
twice daily dosing 
during the study pe-
riod 
United States 30. Okonsky 2011 558 adults-119 
women, 439 men 
Quantitative study  a PI (protease inhibi-
tor)based regimen, symp-
tom experience, other 
health conditions are rea-
sons for missed medica-
tion, wanting to avoid side 
effects, felt sick or ill, too 
many pills to take, felt de-
pressed/overwhelmed, and 
 
  
problems taking pills at 
specified times 
Nigeria, Southwest 31. Okoror et al. 
2013 
35 adults -18 
women, 17 men 
In depth interviews, 
qualitative research 
 Fear for Pre ART sickly 
looking physical manifes-
tation created stigma was a 
paramount factor for ad-
hering to ART. 
belief about adhering 
to ART as the way to 
avoid anticipated 
stigma 
Nigeria, Cross river 32. Oku et al, 2013 411-282 women, 
129 men 
Qualitative study, Cross 
sectional study 
59,9% Main reasons for non-ad-
herence to ART: being 
busy ,simply forgetting 
,depression, frequent trav-
elling and inconvenient 
timing for medications 
schedule  
Positive effects on ad-
herence: non use of 
herbal remedies, ob-
taining free ART ser-
vices, perceived im-
provement in health 
status, and reduced 
pill load. 
South Africa, Kwa-
zulu-natal 
33. Peltzer et al 
2010 
735 adults-219 
women, 516 men 
Qualitative, Cross sec-
tional study, interview 
with a questionnaire 
82,9% Urban residence three 
times higher adherence 
compared to rural resi-
dence. Factors for high ad-
herence: Adequate physi-
cal structure, physical 
health, information. Lower 
adherence: discrimination, 
poor social support, use of 
herb medications for HIV.  
Factors explaining 
difference between 
rural and urban: trans-
portation, access to 
health services 
West Africa, Togo 34. Potchoo et al. 
2010 
99 adults- 76 
women, 23 men. 
Qualitative, Crossed sec-
tional survey, structured 
interview 
62,92% Main causes of non-adher-
ence: Forgetting, travel, 
cost, side-effects.  
Strengthening of 
counselling, educa-
tion and information 
interventions to over-
come potential barri-
ers for adherence 
United States 35. Saberi et al 2011 2845 adults-736 
women, 2109 men 
Quantitative data analy-
sis 
 African Americans higher 
odds of nonadherence in 
comparison to Whites. , 
depression associated with 
 
  
ARV nonadherence,+ 
sleeping problems 
India, West Bengal 36. Saha et al 2014 370 adultas-154 
women, 213 men. 
Recourse poor set-
ting 
Qualitative, Cross sec-
tional study 
- Main causes for non-ad-
herence: forgetting to take 
the medicine, being away 
from home, busy with 
other thing 
positive family his-
tory of HIV was 
found to be the 
strongest predictor of 
non-adherence to 
ART also the pres-
ence of side effects 
with highlight that the 
quality of counselling 
in the ART centre 
needs to be improved. 
Uganda, Kayunga 37. Senkomago et 
al. 2011 
140 Adults-93 
women, 47 men 
Qualitative study, inter-
view 
86,4% Barriers to adherence: be-
ing away from medication 
at dose time, forgetting to 
take pills. Lack of access 
to food and transportation 
costs  
Patients attending ru-
ral clinic were signifi-
cantly less adherent 
Unganda, South West 
Africa, Mbarara 
38. Tuller et al 2010 41 adults-25women, 
16 male using a re-
gional distribution 
point for ARV 
Qualitative study, Semi-
structured interview 
- The lack of funds for 
monthly clinic visits to 
pick up ARV major barrier 
for adherence 
Despite high motiva-
tion for treatment, 
lack of money priority 
United States 39. Tyer-Viola et al 
2014 
382 women Quantitative study, sur-
vey 
 Adherence self-efficacy 
had appositive influence 
on adherence and depres-
sion symptoms negative 
 
Estonia 40. Uuskula et al. 
2012  
144 Adults- 58 
women, 68 men 
Mixed method 
Cros-sectional study, in-
terview survey+data ab-
straction 
88% barriers to ART include 
beliefs about the need for 
treatment and concerns 
about adverse effects, gen-
eral health status (health 
less than good or good), 
active or historical 
IDU was not predic-
tive of non-adherence. 
alcohol use was not 
identified as an influ-
ential factor on ART 
adherence 
  
India, Banhgalore 41. Vallabhaneni et 
al. 2012  
552 adults-177 
women, 375 men 
Quantitative study, inter-
view 
80% Negative effects on adher-
ence: efavirenz-based ther-
apies (used usually with 
tubercoloses infected pati-
etns), being unmarried, 
Side effects, Cost (private-
clinic patients) 
‘‘being busy with 
other things’’, and 
‘‘being away from 
home’’,longer dura-
tion of treatment, 
Vietnam 42. Van Tam et al. 
2011 
48 Adults-12 
women, 6 men 
Qualitative study, inter-
view 
 Stigma was identified as a 
strong barrier to ART ad-
herence, logistical barriers. 
reminders decreased over 
time and this could lead to 
a reduction in ART adher-
ence 
strong desires for adher-
ence support,  PLHIV 
peer-support 
participants did not 
want to receive ART 
medications at home, 
as they feared it might 
increase the risk of 
HIV-related stigma 
South India 43. Venkatesh et al. 
2010 
198 Adults-62 
women 136 men 
Quantitative data review 50,5% Factors for nonadherence: 
poor general health, dis-
tress, alcohol use.  
higher CD4 cell 
counts and a longer 
time period of 
HAART experience 
were less likely to be 
adherent, 
Unites States 
North Carolina 
44. Vissman et al 
2013 
66 adults- 19 
women, 47 men. 
Latino immigrants 
Qualitative, Structured 
interview 
71% Social support was signifi-
cantly and inversely asso-
ciated with adherence, 
 
United States  
Los Angeles 
45. Wagner et al. 
2012 
214- adult men 
African American 
Quantitative study Inter-
view 
22% electronic 
monitoring 
Older and more formal ed-
ucation associated with 
better adherence. Post 
traumatic stress was not 
indicator of poor adher-
ence. however, as symp-
toms become more severe, 
adherence significantly de-
clines 
A greater number of 
discrimination experi-
ences from being gay, 
African American, or 
HIV-positive were 
negatively correlated 
with adherence.  
  
Tanzania 
Free clinic 
46. Watt et al. 2010 340 adults-252 
women, 88 men 
 
Qualitative study, in-
depth interviews 
94% Poor adherence: old 
age(over 50), young age 
(under 30), h less favoura-
ble assessments of their in-
teractions with providers, 
ever missing a clinic ap-
pointment 
 
 
 
 
